Late-onset Hypogonadism: bone health
| Autor: | Vincenzo Rochira |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty medicine.drug_class Hormone Replacement Therapy Urology Endocrinology Diabetes and Metabolism Osteoporosis men Late onset Bone health Risk Assessment 03 medical and health sciences 0302 clinical medicine Endocrinology Bone Density Risk Factors BMD estradiol medicine Animals Humans hypogonadism Eunuchism Testosterone Testosterone replacement Age of Onset 030219 obstetrics & reproductive medicine bone mass business.industry medicine.disease Prognosis Osteopenia Reduced bone mineral density Reproductive Medicine Estrogen male osteoporosis male osteoporosis bone mass bone mineral density BMD men hypogonadism testosterone estradiol testosterone business bone mineral density Biomarkers Osteoporotic Fractures |
| Popis: | Background Bone health is underdiagnosed and undermanaged in men. Bone loss occurs in men with hypogonadism and in aging men. Thus, patients with a diagnosis of late-onset hypogonadism (LOH) are at risk of osteoporosis and osteoporotic fractures. Objectives To provide an update on research data and clinical implications regarding bone health in men with LOH by reviewing literature articles on this issue. Materials and methods A thorough search of listed publications in PubMed on bone health in older men with hypogonadism was performed, and other articles derived from these publications were further identified. Results Late-onset Hypogonadism may be associated with reduced bone mineral density (BMD). In a pathophysiological perspective, the detrimental effects of testosterone (T) deficiency on BMD are partly ascribed to relative estrogen deficiency and both serum T and serum estradiol (E2) need to be above 200 ng/dL and 20 pg/mL to prevent bone loss. The effects of exogenous T on BMD are controversial, but most of the studies confirm that testosterone replacement therapy (TRT) increases BMD and prevents further bone loss in men with hypogonadism. No data are available on TRT and the prevention of fractures. Discussion and conclusion In men with documented LOH, a specific clinical workup should be addressed to the diagnosis of osteoporosis in order to program subsequent follow-up and consider specific bone active therapy. TRT should be started according to guidelines of male hypogonadism while keeping in mind that it may also have positive effects also on bone health in men with LOH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|